Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation. - Qin J; Tang M; Wang X; Shi L; Shao H; Fonseca V; You X (Frontiers in public health, 2026)